FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns treating fatty liver disease. For this purpose, a subject in need thereof is administered a therapeutically effective amount of a glucocorticoid receptor and mineralocorticoid receptor antagonist compound such as (E)-6-(4-phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione or 6-((1r,4r)-4-phenyl-cyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidine-2,4(1H, 3H)-dione.
EFFECT: invention provides treating fatty liver disease.
12 cl, 4 dwg, 5 ex
| Title |
Year |
Author |
Number |
| PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS |
2012 |
|
RU2789326C1 |
| PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS |
2012 |
|
RU2678561C9 |
| METHOD OF TREATING HEPATIC FIBROSES |
2017 |
|
RU2740902C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS |
2021 |
- Kim, Mi-Kyung
- Park, Hansu
- Lee, Seung Ho
|
RU2803733C1 |
| 4-PREGENEN-11Β-17-21-TRIOL-3,20-DIONE DERIVATIVES FOR TREATING EYE DISEASES |
2012 |
- Edelman Dzheffri L.
- Neme Alissar
- Maloun Tomas K.
|
RU2688159C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER |
2017 |
- Ohtani Naoko
- Kamachi Fumitaka
- Loo Tze Mun
- Koizumi Shinichi
- Okumura Takako
|
RU2717331C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER |
2017 |
- Ohtani, Naoko
- Kamachi, Fumitaka
- Loo, Tze Mun
- Koizumi, Shinichi
- Okumura, Takako
|
RU2762193C2 |
| SYNTHESIS AND USE OF TETRAHYDROPYROLLO[3,2-c]PYRIDIN-4-ONE DERIVATIVES TO TREAT OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS |
2006 |
|
RU2415856C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE |
2017 |
- Wu, Edwin, Sc
- Chiu, Peter, J.S.
- Hsu, May, Mei-Chi
|
RU2717677C1 |
| PREVENTIVE AND THERAPEUTIC DRUG FOR NON-ALCOHOLIC FATTY LIVER DISEASE |
2018 |
- Sasaki, Yusuke
- Asahiyama, Masato
- Tanaka, Toshiya
|
RU2820552C2 |
